Clinical Trial Update: A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations [Phase 1]

View source ↗

Summary

Phase 1 pilot study examining the mechanism of synergism between fluticasone propionate and salmeterol in preventing COPD exacerbations; the study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Flovent (fluticasone propionate)
• Serevent (salmeterol)

Snippet

Sponsor: University of Chicago | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED